Sabra Health Care price target raised to $22 from $21 at Jefferies

Jefferies analyst Joe Dickstein raised the firm’s price target on Sabra Health Care (SBRA) to $22 from $21 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for Healthcare REITs. The firm expects another challenging year for lab landlords as elevated market vacancy and a 9.6% decline in trailing-12-month biotech funding will drive below-average retention in 2026, the analyst tells investors in a research note. For Sabra, Jefferies sees upside embedded in the REIT’s SHOP segment while also noting that occupancy and cash net operating income margin are still materially below pre-COVID levels, while supply/demand backdrop is “very attractive”.